Table 1.
Baseline Demographic and Clinical Characteristics, and Follow Up Information of the Entire Cohort and by Anti-Obesity Medication
| All Patients | Phentermine/ Topiramate | Liraglutide | Lorcaserin | Bupropion/ Naltrexone | ANOVA P | |
|---|---|---|---|---|---|---|
| A. Baseline Demographic information | ||||||
| N, % | 304 | n=155 (51.0%) | n=80 (26.3%) | n=19 (6.2%) | n=50 (16.5%) | |
| Age, Years | 50(39–57.8) | 47 (39–56) | 54 (42–63) | 54 (49–63) | 47.5 (38–53) | 0.0009 |
| Sex, Female | 230 (75.7%) | 126 (81.2%) | 48 (60%) | 9 (47.4%) | 47 (94%) | <0.0001 |
| Race, White | 290 (99.0%) | 148 (99.3%) | 76 (97.4%) | 19 (100%) | 47 (100%) | 0.7 |
| B. Baseline Clinical Information | ||||||
| Weight, Kg | 118 (98.2–139.5) | 114.3 (97.5–139.3) | 119.5 (104.0–139.5) | 142.3 (104.4–156.8) | 113.6 (5.7–133.6) | 0.1 |
| BMI, kg/m2 | 41.5 (36.5–47.7) | 41.2 (34.8–47.7) | 42.2 (37.2–47.5) | 44.0 (37.5–50.7) | 41.5 (37.1–48.2) | 0.7 |
| BMI (Class I) | 62 (20.4%) | 39 (25.2%) | 12 (15.0%) | 1 (10.5%) | 9 (18.0%) | 0.5 |
| BMI (Class II) | 56 (18.4%) | 25 (16.1%) | 16 (20.0%) | 5 (26.3%) | 10 (20.0%) | |
| BMI (Class III) | 186 (61.2%) | 91 (58.7%) | 52 (65.0%) | 12 (63.1%) | 31 (62.0%) | |
| SBP, mmHg | 128 (121–137) | 128 (121–136) | 129 (122.8–138.5) | 131 (114–143) | 130 (121–136) | 0.9 |
| DBP, mmHg | 79 (70–86) | 81.5 (73.8–87.2) | 78 (69–85.5) | 89 (69–92) | 77 (73–83) | 0.27 |
| Glucose, mg/dL (n=149) | 105 (93–129) | 100 (92.3–113) | 131 (105–170) | 105 (90–135) | 97 (91–113) | <0.0001 |
| HbA1c, % (n=147) | 6 (5.4–7.2) | 5.5 (5.2–6) | 7.2 (6.2–8.4) | 5.5 (5.1–7.1) | 5.6 (5.1–6.1) | <0.0001 |
| LDL, mg/dL (n=155) | 97 (74–115) | 109 (90.8–123.3) | 81 (60–102) | 82.5 (73.8–95.8) | 97 (80–130) | <0.0001 |
| HDL, mg/dL (n=161) | 46 (39–54.5) | 47 (40.5–62) | 41 (35.5–49) | 34 (30–49) | 52 (44–60) | 0.001 |
| Total Cholesterol, mg/dL (n=161) | 170 (150.5–200.5) | 189 (169–208.8) | 160 (130–192) | 149 (132–160.5) | 175 (155.8–222) | 0.0001 |
| Triglycerides, mg/dL (n=163) | 142 (105–207) | 124 (95–177) | 168 (119.3–229) | 98 (81–257) | 157 (89–218) | 0.1 |
| Dyslipidemia | 161 (53.0%) | 78 (50.3%) | 57 (71.3%) | 6 (31.6%) | 20 (40.0%) | 0.004 |
| Obstructive sleep apnea | 108 (35.5%) | 52 (33.5%) | 36 (45.0%) | 6 (31.6%) | 14 (28.0%) | 0.2 |
| Hypertension | 153 (50.3%) | 63 (40.6%) | 55 (68.7%) | 12 (63.2%) | 21 (42.0%) | 0.0002 |
| Degenerative joint disease | 91 (29.9%) | 51 (32.9%) | 24 (30.0%) | 4 (21.0%) | 12 (24.0%) | 0.5 |
| Diabetes Mellitus | 100 (32.9%) | 22 (14.2%) | 62 (77.5%) | 5 (26.3%) | 11 (22.0%) | <0.0001 |
| GERD | 76 (25.0) | 39 (25.2%) | 20 (25.0%) | 5 (26.3%) | 12 (24.0%) | 0.9 |
| NAFLD | 39 (12.8%) | 17 (11.0%) | 14 (17.5%) | 4 (21%) | 4 (8.0%) | 0.2 |
| # Diabetes meds (n=100) | 1 (0–2) | 0 (0–0.1.5) | 1 (0–2) | 0 | 0 (0–1) | 0.06 |
| # Blood pressure meds (n=153) | 1 (0–1) | 0 (0–1) | 1 (0–2) | 0 (0–1.5) | 0 (0–1.5) | 0.004 |
| # Dyslipidemia meds (n=161) | 0 (0–1) | 0 (0) | 1 (0–1) | 0 | 0 (0–1) | 0.0004 |
| C. Follow up Information | ||||||
| Follow-up, Months | 9.1 (4.2–14.7) | 9.9 (4.2–14.1) | 10.4 (4.9–16.3) | 4.4 (3.3–14.2) | 7.6 (3.2–13.5) | 0.3 |
| Number of follow-up Visits | 3 (2–4) | 3 (2–4) | 3 (2–4) | 3 (2–4) | 3 (2–4) | 0.2 |
| Patients with >1 follow-up visit during year 1 with an obesity specialist | 301 (99.0%) | 153 (98.7%) | 80 (100%) | 19 (100%) | 49 (98.0%) | 0.6 |
| Patients with > 1 follow-up visit during year 2 with an obesity specialist | 138 (45.4%) | 70 (45.1%) | 40 (50.0%) | 7 (36.8%) | 21 (42.0%) | 0.6 |
| Patients with ≥ 1 dietitian visit | 163 (53.6%) | 73 (47.1%) | 47 (58.7%) | 12 (63.2%) | 31 (62.0%) | 0.1 |
| Patients with ≥ 1 psychology visit | 68 (33.5%) | 25 (23.1%) | 23 (42.6%) | 3 (33.3%) | 17 (53.1%) | 0.005 |
Continuous data are summarized as median and interquartile ranges. Categorical data are presented as frequencies and percentages.
All P-values <0.05 were considered significant.
Abbreviations used: BMI, body mass index; DBP, diastolic blood pressure; GERD, gastroesophageal reflux disease; HbA1c; glycated hemoglobin A1c; HDL, high density lipoprotein; LDL, low density lipoprotein; NAFLD, non-alcoholic fatty liver disease; SBP, systolic blood pressure.